Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) insider Mark S. Levine sold 4,361 shares of the firm’s stock in a transaction that occurred on Wednesday, October 23rd. The stock was sold at an average price of $29.53, for a total transaction of $128,780.33. Following the sale, the insider now directly owns 322,878 shares in the company, valued at approximately $9,534,587.34. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Immunovant Trading Down 0.9 %
Shares of IMVT opened at $30.22 on Friday. Immunovant, Inc. has a 12-month low of $24.67 and a 12-month high of $45.58. The stock has a market cap of $4.42 billion, a P/E ratio of -15.66 and a beta of 0.66. The company has a 50-day moving average of $30.07 and a two-hundred day moving average of $28.94.
Immunovant (NASDAQ:IMVT – Get Free Report) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($0.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.07). During the same period last year, the firm earned ($0.57) EPS. As a group, analysts forecast that Immunovant, Inc. will post -2.41 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Check Out Our Latest Research Report on Immunovant
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Wellington Management Group LLP lifted its holdings in shares of Immunovant by 75.0% during the 4th quarter. Wellington Management Group LLP now owns 295,020 shares of the company’s stock worth $12,429,000 after acquiring an additional 126,412 shares during the period. Allspring Global Investments Holdings LLC raised its stake in Immunovant by 51.9% during the first quarter. Allspring Global Investments Holdings LLC now owns 65,091 shares of the company’s stock worth $2,103,000 after purchasing an additional 22,226 shares during the period. Principal Financial Group Inc. boosted its holdings in shares of Immunovant by 32.4% in the 1st quarter. Principal Financial Group Inc. now owns 582,721 shares of the company’s stock valued at $18,828,000 after purchasing an additional 142,606 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Immunovant by 98.3% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 71,788 shares of the company’s stock valued at $2,319,000 after purchasing an additional 35,589 shares during the last quarter. Finally, Sei Investments Co. grew its stake in shares of Immunovant by 11.2% during the 1st quarter. Sei Investments Co. now owns 20,690 shares of the company’s stock valued at $668,000 after buying an additional 2,085 shares during the period. 47.08% of the stock is currently owned by hedge funds and other institutional investors.
Immunovant Company Profile
Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.
Recommended Stories
- Five stocks we like better than Immunovant
- Top Biotech Stocks: Exploring Innovation Opportunities
- Texas Roadhouse Stock Steering for New Highs This Year
- Short Selling: How to Short a Stock
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- Trading Stocks: RSI and Why it’s Useful
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Immunovant Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunovant and related companies with MarketBeat.com's FREE daily email newsletter.